New drug cocktail aims to outsmart tough blood cancers
NCT ID NCT07520006
First seen May 02, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tests a new drug, NX-5948, combined with other medicines (venetoclax and possibly rituximab or obinutuzumab) in adults with B-cell cancers such as lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The goal is to see if the combination is safe and effective for people whose cancer has returned or not responded to prior treatments, as well as for those receiving first-time therapy. About 150 participants will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.